Semaglutide
A GLP-1 receptor agonist approved by the FDA under brand names such as Ozempic and Wegovy for specific medical indications.
What it is
Semaglutide is an engineered version of GLP-1, a gut hormone your body releases after eating. A handful of deliberate amino-acid substitutions stretch its lifespan in the body from minutes to about a week, which is what makes once-weekly dosing possible. It is FDA-approved under the brand names Ozempic (type 2 diabetes) and Wegovy (chronic weight management), with an oral form sold as Rybelsus.
This is one of the most-studied peptides in medicine: large randomized controlled trials measured its effects on blood sugar, body weight and cardiovascular outcomes in tens of thousands of patients. That evidence attaches to the approved products at prescribed doses under medical care — a fact worth holding onto, because an enormous gray market now sells 'semaglutide' outside that system, where neither the contents nor the oversight are guaranteed.
What researchers have actually studied it for
Type 2 diabetes, chronic weight management, and cardiovascular risk reduction — in large human trials run for regulatory approval.
How it works
Semaglutide binds and activates the GLP-1 receptor — the same receptor the natural post-meal hormone hits. Downstream, that slows stomach emptying, quiets appetite signaling in the hypothalamus, and prompts the pancreas to release insulin only when glucose is elevated. The engineered fatty-acid side chain binds blood albumin, which is the trick that stretches its half-life to roughly a week.
Where it came from
GLP-1 biology emerged from gut-hormone research in the 1980s; the first GLP-1 drug (exenatide, from Gila-monster venom peptide research) arrived in 2005. Novo Nordisk's liraglutide followed, and semaglutide — a further-engineered successor — won its first FDA approval in 2017, then reshaped obesity medicine when the STEP trials read out in 2021.
What the research record actually contains
- SUSTAIN program: multi-thousand-patient RCTs in type 2 diabetes establishing glycemic control and cardiovascular safety.
- STEP program: placebo-controlled obesity trials showing roughly 15% average body-weight reduction at the weight-management dose.
- SELECT trial: cardiovascular-outcome benefit demonstrated in adults with obesity and heart disease without diabetes.
- Years of post-market surveillance across millions of patients — rare for anything in this library.
What's known about risks
Characterized in trials and on the label: gastrointestinal effects (nausea, vomiting, constipation) dominate, especially during dose escalation; rarer flagged risks include gallbladder disease and pancreatitis, with a thyroid C-cell tumor warning carried from rodent findings. 'Characterized' is the key word — the risks are documented and managed, which is precisely what gray-market versions forfeit.
Where it stands legally
Prescription-only in every lawful form. During shortage periods, compounded semaglutide flowed through licensed pharmacies; as shortages resolved, FDA moved to wind down mass compounding, and the lawful channel has been narrowing back toward the branded products. Online sellers offering it without a prescription operate outside the system entirely.
Worth asking a licensed provider
- 1.Do I meet the approved criteria for semaglutide, and which branded product fits my situation?
- 2.If a compounded version is proposed, which licensed pharmacy makes it and why is it lawful today?
- 3.What is the plan for side-effect management, monitoring, and — eventually — stopping?
Semaglutide FAQ
Head-to-head
Semaglutide vs. Tirzepatide
GLP-1 vs dual GIP/GLP-1 — how the two most prescribed weight-management peptides compare on evidence, average results, side effects and practical reality.
Semaglutide vs. Liraglutide
Two generations of the same drug class: how the weekly GLP-1 compares with its daily predecessor on results, track record and — increasingly — cost.